Browsing by Autor "Angelica Guzman"
Now showing 1 - 2 of 2
- Results Per Page
- Sort Options
Item type: Item , Follow up study during and after two month regimen of Benznidazole in pediatric chronic Chagas patients in Bolivia(Japanese Pharmacological Society, 2018) Clara Vásquez Velásquez; Emilio E. Espínola; Zunilda Sánchez; Kota Mochizuki; Jimmy Revollo; Angelica Guzman; Benjamín Quiroga; Juan Eiki Nishizawa; Graciela Russomando; Kenji HirayamaIntroduction: Chagas disease is a parasitic infection endemic in Latin America caused by Trypanosoma cruzi. In Bolivia, vector control activity by the National Program for Chagas has greatly decreased the number of natural infections since 2006. The program began a treatment regimen of Benznidazole (BNZ) (5mg/kg/day) for 2 months in seropositive children aged 4-15 years living in certified vector controlled areas.Item type: Item , IL-17A, a possible biomarker for the evaluation of treatment response in Trypanosoma cruzi infected children: A 12-months follow-up study in Bolivia(Public Library of Science, 2019) Clara Vásquez Velásquez; Graciela Russomando; Emilio E. Espínola; Zunilda Sánchez; Kota Mochizuki; Yelin Roca; Jimmy Revollo; Angelica Guzman; Benjamín Quiroga; Susana Rios MorganPlasma levels of IL-17A might be a bio-marker for detecting persistent infection of T. cruzi and its chronic inflammation.